On Thursday, Cronos Group Inc (NASDAQ:CRON) reported fourth-quarter sales of $30.3 million, up from $23.92 million, missing the consensus of $34.95 million.
The increase year-over-year was primarily driven by higher cannabis flower and extract sales in the Canadian market and higher cannabis flower sales in Israel and other countries.
Cronos GrowCo contributed $2.1 million of cannabis flower sales in Q4 2024.
The cannabinoid company reported earnings of 11 cents compared to a loss of 19 cents.
Also Next: Cronos CEO Mike Gorenstein Says He’s Optimistic About Trump’s Impact On Cannabis
The company reported a gross profit of $10.8 million, up from $1.91 million, primarily due to higher sales and production cost improvements. Gross profit was positively impacted by $1.8 million in the quarter in connection with the finalization of the purchase accounting for the Cronos GrowCo Transaction, which resulted in a reduction of the fair value of inventory acquired from Cronos GrowCo and the corresponding inventory step-up previously recorded into the cost of sales.
Adjusted EBITDA loss reached $7.2 million, an improvement of $7.6 million.
“Cronos is well-positioned to capitalize on future opportunities and drive long-term value for our shareholders. As we look ahead to 2025, we remain focused on sustaining this momentum, strengthening our market leadership, and delivering innovative products that resonate with consumers worldwide,” said Mike Gorenstein, chairman, president and CEO of Cronos.
“Our strategic investments, such as Cronos GrowCo, have enhanced our cultivation capabilities, ensuring a consistent supply of high-quality cannabis at scale with an improved gross margin profile, while our R&D breakthroughs have set new industry standards,” Gorenstein added.
Price Action: CRON stock is up 7.87% at $1.9 at the last check Thursday.
Read Next:
Photo: Shutterstock
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。